Conditioned Media-Derived Tumor Extracellular Vesicles: Bridging Molecular Insights and Therapeutic Applications in Oncology.

Authors

Alaya Alkaabi, Dana Nasrallah, Roberta Giordo, Gheyath K Nasrallah, Hatem Zayed, Gianfranco Pintus

Published in

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. Volume 18. Issue 4. Pages e70077.

Abstract

Tumor-derived extracellular vesicles (EVs) are major mediators of oncogenic intercellular communication. However, many studies using conditioned media (CM) recover operationally defined EV- or small EV-enriched fractions rather than biogenesis-proven exosomes. This review synthesizes evidence from CM-derived tumor EV studies and aligns their biological interpretation with current EV nomenclature, characterization, and reporting principles. We first discuss exosome biogenesis as a defined endosomal pathway and then examine how CM collection, serum handling, culture format, oxygen tension, conditioning interval, isolation strategy, storage, and co-isolated material shape EV yield, cargo composition, and apparent biological activity. Mechanistically, CM-based studies have clarified how tumor-derived EV-enriched preparations can support pre-metastatic niche formation, immune evasion through PD-L1 and regulatory RNA cargo, stromal and endothelial remodeling, angiogenesis, and therapy resistance. We also evaluate EV-associated miRNA and protein biomarkers as candidate liquid-biopsy analytes, emphasizing that their diagnostic value remains assay-, cohort-, and workflow-dependent. Therapeutically, the review distinguishes mechanisms inferred from CM-derived tumor EV studies from engineered EV platforms for drug, RNA, cytokine, vaccine, or immune-agonist delivery. Across these areas, we emphasize that robust EV-specific biological interpretations require complementary and methodologically independent characterization, purity and co-isolate assessment, EV-depleted CM, add-back or rescue designs, cargo perturbation, enzymatic controls where appropriate, and dose-normalized functional assays. Advances in microfluidics, immunoaffinity capture, single-vesicle analysis, and multi-omics profiling are improving resolution, but translation will depend on standardized workflows, product- or biomarker-specific validation, scalability, potency metrics, safety, regulatory-grade quality control, and more explicit integration with in vivo and clinically annotated datasets. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

PMID:
42622361
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.